Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Core Insights - Oculis Holding AG has made significant clinical advancements in 2025, particularly in neuro-ophthalmology, with the FDA granting Breakthrough Therapy designation for Privosegtor in optic neuritis, leading to the launch of the PIONEER registrational program [2][4] - The company anticipates three major registrational milestones in 2026, including results from the DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema (DME) and the PREDICT-1 trial for Licaminlimab in dry eye disease [2][3] - Oculis has a strong financial position with cash and short-term investments of $268.7 million as of December 31, 2025, providing a cash runway into 2029 [3][5] Clinical Highlights - Privosegtor has shown promising Phase 2 ACUITY results, leading to its Breakthrough Therapy designation and a potential U.S. market opportunity exceeding $7 billion for optic neuropathies [3][4] - OCS-01 is nearing completion of Phase 3 DIAMOND trials, with over 800 patients enrolled and topline results expected in Q2 2026, targeting a DME market valued at approximately $3 billion [4][5] - Licaminlimab is positioned to transform treatment for dry eye disease with a precision medicine approach, with topline results from the PREDICT-1 trial expected in Q4 2026 [10] Financial Performance - As of December 31, 2025, Oculis reported a net loss of CHF 99.0 million ($119.1 million) for the year, an increase from CHF 85.8 million ($97.4 million) in 2024, primarily due to rising operating expenses [5][15] - Research and development expenses for Q4 2025 were CHF 13.3 million ($16.6 million), up from CHF 11.8 million ($13.4 million) in Q4 2024, reflecting advancements in clinical development [5][15] - General and administrative expenses also increased to CHF 7.8 million ($9.7 million) in Q4 2025 from CHF 5.5 million ($6.3 million) in the same period in 2024, driven by personnel and professional service costs [5][15]